Brain Cancer PDX Models

Suitable preclinical models are needed to evaluate therapies targeting specific pathways which affect brain cancer. Patient-derived xenograft (PDX) models are known to closely reflect human heterogeneity and provide the most accurate approach to predicting an agent’s efficacy prior to entering the clinic. The CrownBio brain cancer PDX collection consists of a wide range of models, including several orthotopic models to more closely recapitulate the tumor microenvironment. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBERCANCER SUBTYPE # per page
BN0769 MeningeomaCLICK TO VIEW
BN10438 GBMCLICK TO VIEW
BN13331 MeningeomaCLICK TO VIEW
BN2276 GBMCLICK TO VIEW
BN2287 GliomaCLICK TO VIEW
BN2289 GliomaCLICK TO VIEW
BN2331 GliomaCLICK TO VIEW
BN2338 GliomaCLICK TO VIEW
BN3733 GBMCLICK TO VIEW
BN3801 NACLICK TO VIEW
BN4045 GBMCLICK TO VIEW
BN5457 NACLICK TO VIEW
BN5459 NACLICK TO VIEW
BN5463 NACLICK TO VIEW
BN5474 GlioblastomaCLICK TO VIEW
BN6299 GliomaCLICK TO VIEW
BN6300 AstrocytomaCLICK TO VIEW
BN6303 GliomaCLICK TO VIEW
BN6304 AstrocytomaCLICK TO VIEW
BN9224 GBMCLICK TO VIEW